Published in Proc Natl Acad Sci U S A on October 21, 2005
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev (2009) 1.91
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol (2009) 1.46
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 1.37
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia (2009) 1.27
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One (2013) 1.21
E2F and p53 induce apoptosis independently during Drosophila development but intersect in the context of DNA damage. PLoS Genet (2008) 1.21
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood (2008) 1.18
Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One (2011) 1.17
Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J Neurosci (2009) 1.13
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11
Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One (2011) 1.09
hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol (2009) 1.06
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One (2012) 1.06
MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia (2009) 1.05
Roles of Kruppel-associated Box (KRAB)-associated Co-repressor KAP1 Ser-473 Phosphorylation in DNA Damage Response. J Biol Chem (2012) 1.04
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol (2010) 1.03
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) (2010) 1.02
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol (2011) 0.99
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther (2009) 0.98
Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profiling. Genome Biol (2007) 0.98
Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res (2010) 0.96
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Conditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure. Mol Endocrinol (2008) 0.94
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res (2014) 0.94
Evidence for involvement of BH3-only proapoptotic members in adenovirus-induced apoptosis. J Virol (2007) 0.93
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer (2010) 0.91
Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma. J Clin Invest (2012) 0.91
Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer. J Biol Chem (2012) 0.91
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood (2016) 0.90
Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells. Cell Death Dis (2012) 0.90
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One (2013) 0.89
Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Mol Pharmacol (2012) 0.89
pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. Cell Death Differ (2013) 0.88
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol (2010) 0.87
Molecular mechanism of SLC5A8 inactivation in breast cancer. Mol Cell Biol (2013) 0.86
Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS One (2014) 0.86
Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol (2016) 0.85
Targeting the regulatory machinery of BIM for cancer therapy. Crit Rev Eukaryot Gene Expr (2012) 0.84
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res (2012) 0.84
Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation. Radiat Oncol (2014) 0.83
Identification of a candidate alternative promoter region of the human Bcl2L11 (Bim) gene. BMC Mol Biol (2008) 0.82
The pro-apoptotic activity of Drosophila Rbf1 involves dE2F2-dependent downregulation of diap1 and buffy mRNA. Cell Death Dis (2014) 0.82
Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med (2010) 0.82
Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells. ACS Med Chem Lett (2013) 0.81
Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells. Gynecol Oncol (2007) 0.81
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. Clin Cancer Res (2016) 0.80
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
RhoB upregulation leads to either apoptosis or cytostasis through differential target selection. Endocr Relat Cancer (2015) 0.78
Integrative biology--a strategy for systems biomedicine. Nat Rev Genet (2009) 0.78
Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev (2011) 0.78
To live or let die - complexity within the E2F1 pathway. Mol Cell Oncol (2015) 0.78
E2F transcription factor 1 regulates cellular and organismal senescence by inhibiting Forkhead box O transcription factors. J Biol Chem (2014) 0.77
Vorinostat-An Overview. Indian J Dermatol (2015) 0.77
Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 0.77
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiat Oncol (2015) 0.76
Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells. Int J Mol Sci (2016) 0.75
Bim regulation miRrors microRNA 17∼92 cluster expression in endothelial cells in vivo. Cell Death Differ (2014) 0.75
Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo. Am J Transl Res (2016) 0.75
A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. Oncotarget (2017) 0.75
Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer. Int J Nanomedicine (2017) 0.75
Cancer cell cycles. Science (1996) 21.29
The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77
PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 11.04
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (2003) 9.94
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem (1990) 9.21
Intrinsic tumour suppression. Nature (2004) 8.73
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J (1998) 7.17
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol (2000) 6.05
BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature (2002) 5.98
Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A (2004) 5.55
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol (2001) 4.83
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46
pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev (1997) 4.36
FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol (2003) 4.31
Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol (2003) 4.25
Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A (1995) 3.95
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A (1998) 3.62
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet (2000) 3.03
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol (2002) 2.86
CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol (1999) 2.84
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J (1996) 2.63
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 2.61
The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol (1998) 2.53
Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem (2003) 2.41
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 2.29
Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol (2003) 2.24
Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell (2003) 2.20
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07
Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol (2002) 2.04
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84
Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene (2003) 1.76
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem (2004) 1.70
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A (1999) 1.65
E2F1 and c-Myc in cell growth and death. Cell Cycle (2003) 1.64
Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ (2005) 1.57
Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol (2004) 1.57
Gene expression changes in response to E2F1 activation. Nucleic Acids Res (2002) 1.44
Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol (2002) 1.26
Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res (2003) 1.24
E2F1 pathways to apoptosis. FEBS Lett (2002) 1.20
E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev (2000) 1.20
A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth Differ (1999) 1.14
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours. Oral Oncol (2004) 1.02
Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets (2002) 0.84
Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica (1999) 0.80
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
Mapping human genetic diversity in Asia. Science (2009) 7.40
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 5.99
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res (2009) 4.47
Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell (2012) 3.92
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature (2010) 3.54
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity (2002) 3.46
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell (2010) 2.44
Impact of agricultural management practices on soil organic carbon: simulation of Australian wheat systems. Glob Chang Biol (2013) 2.37
Regulation of estrogen receptor-mediated long range transcription via evolutionarily conserved distal response elements. J Biol Chem (2008) 2.34
Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet (2005) 2.32
Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell (2004) 2.29
Derepression of ethylene-stabilized transcription factors (EIN3/EIL1) mediates jasmonate and ethylene signaling synergy in Arabidopsis. Proc Natl Acad Sci U S A (2011) 2.25
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A (2002) 2.15
Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell (2011) 2.12
Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription- independent poising of chromatin. Immunity (2010) 2.08
Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res (2004) 2.05
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol (2010) 2.04
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A (2010) 1.91
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev (2009) 1.91
Environment. Building a "green" railway in China. Science (2007) 1.73
Electronic nicotine delivery systems: regulatory and safety challenges: Singapore perspective. Tob Control (2012) 1.70
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem (2004) 1.70
Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn (2002) 1.67
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res (2012) 1.67
Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy. FEBS Lett (2009) 1.65
5' Long serial analysis of gene expression (LongSAGE) and 3' LongSAGE for transcriptome characterization and genome annotation. Proc Natl Acad Sci U S A (2004) 1.64
Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4. EMBO J (2007) 1.59
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res (2004) 1.57
The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet (2010) 1.56
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res (2008) 1.55
Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol (2011) 1.55
FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res (2011) 1.55
Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis (2012) 1.53
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol (2005) 1.51
Systematic deletion analysis of fission yeast protein kinases. Eukaryot Cell (2005) 1.51
[Effects of different statin regimens on lipid profile and serum metalloproteinases in patients with coronary heart disease]. Zhonghua Xin Xue Guan Bing Za Zhi (2009) 1.50
Mitochondrial electron transport chain complex III is required for antimycin A to inhibit autophagy. Chem Biol (2011) 1.50
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood (2011) 1.49
Dragon ERE Finder version 2: A tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. Nucleic Acids Res (2003) 1.49
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol (2012) 1.46
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem (2003) 1.40
Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell (2013) 1.40
De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One (2009) 1.39
Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res (2002) 1.38
Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res (2005) 1.38
Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene (2005) 1.36
The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res (2002) 1.35
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res (2002) 1.34
Optimal gene expression analysis by microarrays. Cancer Cell (2002) 1.34
Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res (2002) 1.32
Genetic background is an important determinant of metastatic potential. Nat Genet (2003) 1.31
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol (2011) 1.26
Heparan sulfate-FGF10 interactions during lung morphogenesis. Dev Biol (2003) 1.24